References
- Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis 2011;70(Suppl 1):i2–36.
- D’Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?. Am J Gastroenterol 2011;106:199–212.
- Buccoliero G, Lonero G, Romanelli C, Loperfido P, Resta F. Varicella zoster virus encephalitis during treatment with anti-tumor necrosis factor-alpha agent in a psoriatic arthritis patient. New Microbiol 2010;33:271–4.
- Bradford RD, Pettit AC, Wright PW, Mulligan MJ, Moreland LW, McLain DA, et al. Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors. Clin Infect Dis 2009;49:924–7.
- Whitley RJ, Lakeman F. Herpes simplex virus infections of the central nervous system: therapeutic and diagnostic considerations. Clin Infect Dis 1995;20:414–20.
- Hacke W. German trial of Acyclovir and Corticosteroids in Herpes-simplex-virus-Encephalitis (GACHE). ISRCTN Register. Available at: http://www.controlledtrials.com/ISRCTN45122933 (accessed 19 February 2013).
- Benucci M, Saviola G, Manfredi M, Sarzi-Puttini P, Atzeni F. Tumor necrosis factors blocking agents: analogies and differences. Acta Biomed 2012;83:72–80.
- Patkar NM, Teng GG, Curtis JR, Saag KG. Association of infections and tuberculosis with antitumor necrosis factor alpha therapy. Curr Opin Rheumatol 2008;20:320–6.
- Kim SY, Solomon DH. Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol 2010;6: 165–74.
- FDA Adverse Events Reporting System (FAERS). Available at: http://www.fda.gov (accessed 16 August 2012).
- Benedict CA, Ware CF. Virus targeting of the tumor necrosis factor superfamily. Virology 2001;289:1–5.
- Lundberg P, Welander PV, Edwards CK 3rd, van Rooijen N, Cantin E. Tumor necrosis factor (TNF) protects resistant C57BL/6 mice against herpes simplex virus-induced encephalitis independently of signaling via TNF receptor 1 or 2. J Virol 2007;81:1451–60.
- Vilela MC, Lima GK, Rodrigues DH, Lacerda-Queiroz N, Mansur DS, de Miranda AS, et al. TNFR1 plays a critical role in the control of severe HSV-1 encephalitis. Neurosci Lett 2010;479:58–62.
- Aurelius E, Andersson B, Forsgren M, Sköldenberg B, Strannegård O. Cytokines and other markers of intrathecal immune response in patients with herpes simplex encephalitis. J Infect Dis 1994;170:678–81.
- A phase III double-blind, placebo-controlled trial of long term therapy of herpes simplex encephalitis (HSE): an evaluation of valacyclovir. Study identifier: NCT00031486. Available at: http://www.clinicaltrials.gov (accessed 19 February 2013).